Page last updated: 2024-08-23

paroxetine and ciprofloxacin

paroxetine has been researched along with ciprofloxacin in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (21.43)29.6817
2010's11 (78.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Cecchetti, V; Gosetto, F; Kaatz, GW; Manfroni, G; Patel, D; Sabatini, S; Tabarrini, O1
Brincat, JP; Carosati, E; Cecchetti, V; Gosetto, F; Iraci, N; Kaatz, GW; Manfroni, G; Sabatini, S; Serritella, S; Tabarrini, O; Villarini, M1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Barreca, ML; Cecchetti, V; Dimovska, M; Gosetto, F; Iraci, N; Kaatz, GW; Manfroni, G; Massari, S; Sabatini, S; Sancineto, L; Tabarrini, O1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Avorn, J; Bohn, RL; Daniel, GW; Eisenberg, DF; Gagne, JJ; Patrick, AR; Rassen, JA; Rodgers, JK; Schneeweiss, S; Wahl, PM; Wasser, TE; Wilson, M1
Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S1

Reviews

1 review(s) available for paroxetine and ciprofloxacin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

13 other study(ies) available for paroxetine and ciprofloxacin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
    Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Synergism; Flavones; Hydroxyquinolines; Microbial Sensitivity Tests; Models, Chemical; Molecular Structure; Multidrug Resistance-Associated Proteins; Mutation; Species Specificity; Staphylococcus aureus; Structure-Activity Relationship

2011
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
    Journal of medicinal chemistry, 2012, Apr-12, Volume: 55, Issue:7

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Resistance, Multiple, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Models, Molecular; Multidrug Resistance-Associated Proteins; Pyrazoles; Small Molecule Libraries; Staphylococcus aureus; Structure-Activity Relationship; Sulfonamides; Thiazines

2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
    Journal of medicinal chemistry, 2013, Jun-27, Volume: 56, Issue:12

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Chemistry Techniques, Synthetic; Computer-Aided Design; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Inhibitory Concentration 50; Ligands; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Multidrug Resistance-Associated Proteins; Quinolines; Staphylococcus aureus; Structure-Activity Relationship

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.
    Drug safety, 2012, May-01, Volume: 35, Issue:5

    Topics: Achilles Tendon; Adverse Drug Reaction Reporting Systems; Algorithms; Angioedema; Anti-Infective Agents; Antihypertensive Agents; Ciprofloxacin; Databases, Factual; Drug Monitoring; Electronic Health Records; Gastrointestinal Hemorrhage; Humans; Lisinopril; Paroxetine; Pilot Projects; Prospective Studies; Rupture; Selective Serotonin Reuptake Inhibitors; Time Factors

2012
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
    Biopharmaceutics & drug disposition, 2018, Volume: 39, Issue:1

    Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software

2018